Vaginal Microbiota Transplant (VMT): A Step Forward in Treating Vaginal Dysbiosis

Antibiotic-free vaginal microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent pregnancy loss:

In an innovative study, Tine Wrønding, Kilian Vomstein, and collaborators delve into the transformative potential of Vaginal Microbiota Transplantation (VMT) for addressing vaginal dysbiosis without traditional antibiotics. Their groundbreaking research reveals new hope for patients experiencing recurrent pregnancy loss.

Vaginal Microbiota Transplant - download paper


Understanding Vaginal Dysbiosis and its Challenges

Vaginal dysbiosis (VD) is an imbalance in the vaginal microbiota. It can be linked to various health complications, such as fertility issues, premature births, and recurrent pregnancy losses. Astonishingly, between 18-29% of women experience VD, yet many show no evident symptoms. Traditionally, VD is treated with antibiotics, which although effective, often lead to recurrence and may foster antibiotic-resistant bacteria. With recurrence rates of up to 60% within a year of treatment, there’s an urgent call for alternative solutions.

The Potential of Vaginal Microbiota Transplantation (VMT)

A recent study introduced VMT as a promising alternative. VMT is, in essence, the transfer of a healthy vaginal microbiome from a donor to a recipient. Initial studies used antibiotics before performing VMT, achieving long-term remission in four out of five patients. This new research, however, showcases the first successful VMT without prior antibiotic treatment on a 30-year-old woman. She had suffered from recurrent VD for nine years and faced multiple late pregnancy losses. Following the VMT, not only was her VD rectified, but she also experienced a successful pregnancy and birth.


The Key to Success: Donor Engraftment and Future Implications

One major breakthrough in this study was the ability to confirm donor engraftment through shotgun metagenomic sequencing. In simple terms, scientists could pinpoint that the success of the VMT was genuinely due to the transferred microbiome and not an external factor or residual bacteria in the patient. This technique could pave the way for more targeted and effective VMTs in the future. While the exact mechanism of how VMT impacts the entire vaginal microbial community remains a mystery, the study presents a strong case for its potential in treating not only VD but also VD-associated complications during pregnancies or IVF procedures.

In conclusion, this pioneering research heralds a potential new era in women’s health, offering hope for sustainable treatments for VD without the setbacks of antibiotics. Future studies and controlled trials will be critical in establishing VMT’s role as a revolution



Tine Wrønding, Kilian Vomstein, et al. “Antibiotic-free vaginal microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent pregnancy loss: a proof of concept case study” eClinicalMedicine (2023).

Journal Authors:

Tine Wrønding, Kilian Vomstein, Elleke F. Bosma, Brynjulf Mortensen, Henrik Westh, Julie Elm Heintz,Sarah Mollerup, Andreas Munk Petersen, Laura M. Ensign, Kevin DeLong, Johan E.T. van, Hylckama Vlieg, Anne Bloch Thomsen, Henriette Svarre Nielsen